Accuray Inc splits its revenue into 2 lines in its filings. The largest line in fiscal 2026, which ended Jun 30, 2026 was Services at $229.2 million, 57% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
FY 2019
Jun 30, 2019
|
FY 2018
Jun 30, 2018
|
FY 2017
Jun 30, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
402
|
459
|
447
|
448
|
430
|
396
|
383
|
419
|
405
|
383
|
| Services |
229
+3.8%
share 57.0%
|
221
+4.0%
share 48.2%
|
212
-0.9%
share 47.6%
|
214
-0.4%
share 47.9%
|
215
-2.0%
share 50.1%
|
220
+1.9%
share 55.4%
|
216
-2.9%
share 56.3%
|
222
+0.5%
share 53.0%
|
221
share 54.6%
|
—
|
| Product |
173
-27.3%
share 43.0%
|
238
+1.5%
share 51.8%
|
234
+0.4%
share 52.4%
|
233
+8.6%
share 52.1%
|
215
+21.6%
share 49.9%
|
177
+5.6%
share 44.6%
|
167
-14.9%
share 43.7%
|
197
+6.9%
share 47.0%
|
184
share 45.4%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- ARAY (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Madison, WI
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1138723
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.